Restless Legs Syndrome: Cannabinoids Show Promising Results, but the Evidence Remains Weak

A new scientific journal is reigniting the debate over the role of Cannabinoids in Restless Legs Syndrome (RLS). Published in the Annals of the Indian Academy of Neurology, an analysis of seven studies concludes that there is potential therapeutic benefit, particularly for the CBD, while highlighting the significant gaps in current research.

The restless legs syndrome, also known as Willis-Ekbom disease, is a neurological disorder characterized by an irresistible urge to move the legs, usually accompanied by unpleasant sensations such as tingling, pulling, or pain. Symptoms appear or worsen mainly at rest, in the evening, and at night, which can affect sleep and quality of life.

Given the limitations of certain conventional treatments, researchers at the All India Institute of Medical Sciences set out to examine what the scientific literature actually says about the use of cannabis and cannabinoids for RLS.

The literature on cannabinoids and RLS remains limited

The researchers combed through several major scientific databases, including PubMed, Embase, Scopus, the Cochrane Library, Google Scholar, and ClinicalTrials.gov. Their search identified 5,370 items, before removing duplicates and selecting relevant studies.

At the end of the process, only seven studies met the inclusion criteria. The main finding of the review: the initial findings are promising, but the quantity and, above all, the quality of the available data do not yet allow for solid clinical conclusions.

The authors cautiously summarize their position: «The available data suggest that cannabis or cannabidiol may alleviate or prevent the symptoms of restless legs syndrome.»

In other words, there is some evidence of efficacy, but it still needs to be confirmed in more rigorous studies.

Improvements reported in some patients

Nevertheless, several of the studies analyzed present results that are significant enough to warrant further research.

A series of six patients who had been suffering from a particularly severe RLS for several years reported a complete resolution of symptoms following spontaneous cannabis use. These individuals had previously been undergoing various treatments, including dopamine agonists, alpha-2-delta ligands, or opioids.

Another study focusing on patients with severe to very severe RLS also reported complete or nearly complete improvement in all but one participant after smoking cannabis. Three patients who subsequently tried Sublingual CBD However, they reported that smoking cannabis provided them with greater relief.

The results are less consistent in other populations. Among people with end-stage renal disease undergoing dialysis, half of the patients who used cannabis to treat their symptoms reported that their RLS had completely disappeared.

Conversely, an analysis focusing on people with Parkinson's disease shows a much more limited response: among cannabis users who also suffer from RLS, only six out of 28 participants reported an improvement.

These discrepancies highlight a key challenge: the term «cannabis» encompasses a wide range of products, dosages, routes of administration, and cannabinoid profiles.

CBD, Medical Cannabis, and Routes of Administration: Results That Are Difficult to Compare

The journal specifically cautions against interpreting the results in an overly uniform manner. In some studies, the cannabinoid-based products appear to be associated with an improvement in symptoms. In particular, a topical application containing CBD has been linked to a significant improvement after two weeks.

However, a clinical trial evaluating oral medical cannabis, at doses of up to 300 mg per day, did not demonstrate any improvement in RLS or periodic limb movements during sleep.

The researchers also note that studies vary widely in terms of doses, formulations, and methods of administration. Differences in concentration of THC and CBD, the actual amount absorbed, and associated treatments may all contribute to the observed results.

The journal therefore emphasizes a key point: Cannabis is not a single, standardized therapeutic intervention.

The Possible Role of Iron and the Endocannabinoid System

The authors also highlight a factor that may influence the response to treatment: the iron status patients.

Iron plays an important role in the biological mechanisms associated with RLS, and optimizing iron levels is already a key component of treatment. Several of the studies reporting the best responses to cannabinoids involved patients with adequate iron stores.

However, based on the available data, it remains impossible to determine whether iron status directly influences the response to cannabinoids.

From a biological perspective, researchers have proposed several mechanisms that could explain a possible effect. The endocannabinoid system, particularly through the CB1 and CB2 receptors, plays a role in several neurological functions. It can modulate systems involving dopamine, opioids, norepinephrine, serotonin, GABA, and glutamate.

These interactions could theoretically help reduce certain phenomena associated with RLS, particularly the hyperactivity observed during the onset of sleep. However, these mechanisms remain largely hypothetical and need to be tested against more robust clinical data.

For now, therefore, the message from this scientific review remains cautious. Cannabinoids—and CBD in particular—show promising therapeutic potential for restless legs syndrome, but the available evidence is still too limited to justify routine use. The next step will be to translate these preliminary observations into clinical trial data robust enough to determine whether this approach can truly become part of the management of RLS.